Company News: Dendreon

Share this article:
Dendreon's Provenge prostate cancer vaccine, the first in a new class of cancer treatments that use the patient's own immune system, received FDA approval. The vaccine, approved for men with the advanced form of the disease, is designed to induce an immune response against prostatic acid phosphatase, an antigen expressed in most prostate cancers. Provenge (sipuleucel-T) belongs to a new therapeutic class called autologous cellular immunotherapies and could usher in an entirely new treatment paradigm for patients with cancer. Several other companies are developing immunotherapies targeting tumor antigens.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Illumina inks deal with J&J, AstraZeneca, Sanofi

The goal is to develop companion diagnostics to match patients with cancer treatments.

Abbott deal highlights inversion inaction

Political furor over the recent spate of tax inversions is having little influence on how the government chooses its partners.

Allergan reported to seek out Salix deal

The Wall Street Journal says the deal would add "another layer of intrigue" to the Allergan-Valeant hostilities.